{
    "organizations": [],
    "uuid": "ddbbc0961f8b9bc4ee973ad72b73e1be6b62be90",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-orphazyme-granted-rare-pediatric-d/brief-orphazyme-granted-rare-pediatric-disease-designation-by-fda-idUSFWN1PD1J7",
    "ord_in_thread": 0,
    "title": "BRIEF-Orphazyme Granted Rare Pediatric Disease Designation By FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - ORPHAZYME A/S:\n* REG-ARIMOCLOMOL FOR NPC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION\n* ORPHAZYME A/S - ARIMOCLOMOL HAS BEEN GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY US FOOD AND DRUG ADMINISTRATION\n* ORPHAZYME A/S - ARIMOCLOMOL FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE C (NPC). Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-19T15:27:00.000+02:00",
    "crawled": "2018-01-20T17:34:24.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "orphazyme",
        "npc",
        "receives",
        "rare",
        "pediatric",
        "disease",
        "designation",
        "orphazyme",
        "arimoclomol",
        "granted",
        "rare",
        "pediatric",
        "disease",
        "designation",
        "u",
        "food",
        "drug",
        "administration",
        "orphazyme",
        "arimoclomol",
        "treatment",
        "disease",
        "type",
        "c",
        "npc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}